MIRA INFORM REPORT
|
Report No. : |
339258 |
|
Report Date : |
03.09.2015 |
IDENTIFICATION DETAILS
|
Name : |
QILU ANTIBIOTICS PHARMACEUTICAL CO., LTD. |
|
|
|
|
Registered Office : |
No.
849, Dongjia Town, Licheng District, Ji’nan, Shandong Province, 250105 Pr |
|
|
|
|
Country : |
China |
|
|
|
|
Date of Incorporation : |
29.05.1995 |
|
|
|
|
Com. Reg. No.: |
370000400001223 |
|
|
|
|
Legal Form : |
Chinese-Foreign Equity Joint Venture Enterprise |
|
|
|
|
Line of Business : |
Subject is
mainly engaged in researching, developing, manufacturing and selling
cephalosporin products. |
|
|
|
|
No. of Employees : |
600 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
CHINA - ECONOMIC OVERVIEW
Since the late 1970s China has moved from a closed, centrally planned system to a more market-oriented one that plays a major global role - in 2010 China became the world's largest exporter. Reforms began with the phasing out of collectivized agriculture, and expanded to include the gradual liberalization of prices, fiscal decentralization, increased autonomy for state enterprises, growth of the private sector, development of stock markets and a modern banking system, and opening to foreign trade and investment. China has implemented reforms in a gradualist fashion. In recent years, China has renewed its support for state-owned enterprises in sectors considered important to "economic security," explicitly looking to foster globally competitive industries. After keeping its currency tightly linked to the US dollar for years, in July 2005 China moved to an exchange rate system that references a basket of currencies. From mid 2005 to late 2008 cumulative appreciation of the renminbi against the US dollar was more than 20%, but the exchange rate remained virtually pegged to the dollar from the onset of the global financial crisis until June 2010, when Beijing allowed resumption of a gradual appreciation. In 2014 the People’s Bank of China (PBOC) doubled the daily trading band within which the RMB is permitted to fluctuate. The restructuring of the economy and resulting efficiency gains have contributed to a more than tenfold increase in GDP since 1978. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, China in 2014 stood as the largest economy in the world, surpassing the US that year... Still, per capita income is below the world average.
The Chinese government faces numerous economic challenges, including: (a) reducing its high domestic savings rate and correspondingly low domestic consumption; (b) facilitating higher-wage job opportunities for the aspiring middle class, including rural migrants and increasing numbers of college graduates; (c) reducing corruption and other economic crimes; and (d) containing environmental damage and social strife related to the economy's rapid transformation. Economic development has progressed further in coastal provinces than in the interior, and by 2014 more than 274 million migrant workers and their dependents had relocated to urban areas to find work. One consequence of population control policy is that China is now one of the most rapidly aging countries in the world. Deterioration in the environment - notably air pollution, soil erosion, and the steady fall of the water table, especially in the North - is another long-term problem. China continues to lose arable land because of erosion and economic development. The Chinese government is seeking to add energy production capacity from sources other than coal and oil, focusing on nuclear and alternative energy development.
Several factors are converging to slow China's growth, including debt overhang from its credit-fueled stimulus program, industrial overcapacity, inefficient allocation of capital by state-owned banks, and the slow recovery of China's trading partners. The government's 12th Five-Year Plan, adopted in March 2011 and reiterated at the Communist Party's "Third Plenum" meeting in November 2013, emphasizes continued economic reforms and the need to increase domestic consumption in order to make the economy less dependent in the future on fixed investments, exports, and heavy industry. However, China has made only marginal progress toward these rebalancing goals. The new government of President XI Jinping has signaled a greater willingness to undertake reforms that focus on China's long-term economic health, including giving the market a more decisive role in allocating resources. In 2014 China agreed to begin limiting carbon dioxide emissions by 2030. China implemented several economic reforms in 2014, including passing legislation to allow local governments to issue bonds, opening several state-owned enterprises to further private investment, loosening the one-child policy, passing harsher pollution fines, and cutting administrative red tape.
|
Source
: CIA |
Company
name and address
QILU ANTIBIOTICS PHARMACEUTICAL CO., LTD.
NO. 849, DONGJIA
TOWN, LICHENG DISTRICT, JI’NAN,
SHANDONG PROVINCE,
250105 PR CHINA
TEL: 86 (0)
531-83128660/83128662 FAX: 86 (0)
531-83128687
EXECUTIVE
SUMMARY
INCORPORATION DATE : MAY 29, 1995
REGISTRATION NO. : 370000400001223
REGISTERED LEGAL FORM : CHINESE-FOREIGN EQUITY
JOINT VENTURE ENTERPRISE
STAFF STRENGTH : 600
REGISTERED CAPITAL : USD 20,504,100
BUSINESS LINE :
RESEARCHING & DEVELOPING, MANUFACTURING AND TRADING
TURNOVER : N/A
EQUITIES : N/A
PAYMENT : AVERAGE
MARKET CONDITION : COMPETITIVE
FINANCIAL CONDITION : N/A
OPERATIONAL TREND :
STEADY
GENERAL REPUTATION : WELL-KNOWN
EXCHANGE RATE : CNY 6.4177 = USD
1
Adopted
abbreviations:
ANS - amount not
stated
NS - not stated
SC - subject company
(the company inquired by you)
NA - not available
CNY - China Yuan Ren Min Bi
SC was registered as a Chinese-foreign equity
joint venture enterprise at Shandong Provincial Administration for Industry
& Commerce (AIC - The official body of issuing and renewing business
license) on May 29, 1995.
Company Status: Chinese-foreign equity joint venture
enterprise This form of business in PR
China is defined as a legal person. It is a limited co. jointly invested by
one or more foreign companies and one or more PR China controlled companies
within the territories of PR China according to a certain proportion of
capital investment. The investing parties exercise business management,
share profits and bear all risks and liabilities of the co. together. The
equity joint venture law requires that foreign party contribute not less
than 25% of the registered capital, with no maximum. The investing parties
are free to agree on method of profit distribution and liabilities bearing
according to the proportion of capital investment. Each investing parties
contributes funds, tangible assets, technology & etc. The board of
directors excises the high authority. The joint venture usually has a
limited duration of 10 to 50 years. Enterprise with large investment, long
construction periods, low investment returns, introducing of advanced
technology & advanced technology products that have good competition
position in international market may extend beyond the 50 years limit.
SC’s registered
business scope includes manufacturing and selling cephalosporin pharmaceutical
products and pharmaceutical intermediates and by-products, researching and
developing penicillin products (with permit if needed).
SC is mainly engaged
in researching, developing, manufacturing and selling cephalosporin products.
Mr. Hou Chuanshan
is legal representative, chairman and general manager of SC at present.
SC is known
to have approx. 600 employees at present.
SC
is currently operating at the above stated address, and this address houses its
operating office and factory in the industrial zone of Ji’nan. Our checks
reveal that SC owns the total premise about 25,000 square meters.
http://www.qilu-antibiotics.com/
The design is professional and the content is well organized. At present it is
in both Chinese and English versions.
Email: export@qilu-antibiotics.com
Honors:
=====
*In January 2006, SC was awarded “Advanced Enterprise in Foreign Trade
in the Year
*In January 2005, SC was awarded “Advanced Enterprise in Industry In-put
in the Year
*In January 2004, SC was awarded “Big Contribution Enterprise in Revenue
in the Year
*In January 2004, SC was awarded “Advanced Enterprise in Foreign Trade
of Industry System”
*In January 2004, SC was appraised as “Advanced Enterprise of Safe
Production”
*In March 2003, SC was awarded “Advanced Enterprise in Foreign Trade of
Industry System” by Jinan Foreign Trade & Economy Committee.
*In July 2002, SC was awarded “Youth Civilization Group” by Shandong
Labor Committee.
*In March 2002, SC was awarded “Advanced Enterprise in Utilizing Foreign
Capital” by Jinan city government.
*In June 2002, SC was awarded “The Best Foreign Investigation Enterprise
of Jinan City” by Jinan city government.
*In March 2002, SC was awarded “AA Class Enterprise by Custom of
Republic of China” by the Custom.
*In 2002, SC was awarded “Double-Excellent Enterprise in the Year
*In 2001, SC was awarded “One of The Best Foreign Investigation
Enterprise” by Jinan city government.
*In 2000, SC was awarded “The Visualizing Foreign Enterprise of Jinan”
by Jinan city government.
Changes
of its registered information:
|
Date of change |
Item |
Before the change |
After the change |
|
Unknown |
Registered No. |
003642 |
370000400001223 |
|
Chinese Name |
|
|
|
|
2007-6-29 |
Registered Capital |
USD 12,500,000 |
USD 19,700,000 |
|
2011 |
Registered capital |
USD 19,700,000 |
Present amount |
|
Shareholders (% of shareholding) |
Qilu Pharmaceutical
Co., Ltd. 49% Antibiotics Hong Kong International
Limited 51% |
Present ones |
Note: SC changed its Chinese name, while its English name remains the
same.
Tax registration no.: 370112614074047
Organization code: 614074047
For the past two years there is no record of litigation.
MAIN
SHAREHOLDERS:
Name %
of Shareholding
Qilu Pharmaceutical Co., Ltd. 51.00
Antibiotics Hong Kong International Limited 49.00
Qilu Pharmaceutical Co., Ltd.
=====================
It focuses on developing, manufacturing and
marketing generic drugs in therapeutic area of Oncology, Cerebrovascular &
Cardiovascular, Infections, Psychological and Neurological system, Respiratory
system, Ophthalmologic Diseases etc., as well as active pharmaceutical
ingredients.
Address: No. 243, Gongye North Road, Jinan,
Shandong Province
Tel: 86-531- 83127705/ 83127704/83127706/
83127707/ 83127709/ 83127711/ 83127712
Fax: 86-531- 83127700
E-mail: export@qilu-pharma.com
Web: http://www.qilu-pharma.com
Registered no.: 370000228034515
Legal representative: Li Botao
Registered capital: CNY 600,000,000
Date of incorporation:
Legal form: One-person Limited Liability Company
Antibiotics Hong Kong International Limited
================================
Registered number: 0463233
Incorporated date: Feb. 1, 1994
Legal form: Private company limited by
shares
Active Status: Live
l Legal
representative, chairman and general manager:
Mr. Hou Chuanshan, born in 1965 with
university education. He is currently responsible for the overall management of
SC.
Working Experience(s):
At present Working in SC as legal
representative, chairman and general manager
Also working in Qilu Antibiotics (Linyi) Pharmaceutical Co.,
Ltd. as legal representative
l Directors:
Sun Tongshun
Zhao Weiliang
Chen Lianbing
Bao Haizhong
SC is mainly
engaged in researching, developing, manufacturing and selling cephalosporin
products.
SC’s products
mainly include:
Cefepime
Dihydrochloride Sterile(L - Arginine) (USDMF/ (EDMF))
Cefpirome Sulfate Sterile(Sodium
Carbonate)
Cefuroxime Sodium
(CEP)
Cefoperazone
Sodium + SulbactamSodium(1:1)
Cefoperazone
Sodium (CEP)
Cefotaxime Sodium
(TGA/CEP)
Cefazolin Sodium
(TGA/CEP)
Ceftriaxone Sodium
(TGA/CEP)
Ceftazidime(L -
Arginine)
Ceftazidime(Sodium
Carbonate) (TGA)
Ceftazidime
Pentahydrate
Cefprozil (USDMF)
Cefixime
Cefdinir
Cefteram Pivoxil
Cefotiam
Hydrochloride
Ceftizoxime Acid
Ceftezole Acid
Cefuroxime Acid
Cefepime
Hydrochloride
SC is one of the
largest bulk Cephalosporin production bases in China. It is the forthgoer among
other competitors to have undergone GMP (Good Manufacture Practice) approved by
the China State Drug Administration (SDA).
SC sources its
materials 80% from domestic market, and 20% from the overseas market, mainly
Europe. SC sells 90% of its products in domestic market, and 10% to the
overseas market, mainly Europe.
The buying terms of SC include Check, T/T, L/C and Credit of 30-60 days.
The payment terms of SC include T/T, L/C and Credit of 30-60 days.
Trademark &
Patents
|
Registration
No. |
7946216 |
|
Registration
Date |
|
|
Trademark
Design |
|
Note: SC’s management refused to release its
main clients and suppliers.
SC is known to invest in the following company:
Qilu Antibiotics (Linyi) Pharmaceutical Co.,
Ltd.
==================================
Date of incorporation:
Registered no.: 371424200001217
Registered capital: CNY 30,000,000
Legal representative: Hou Chuanshan
Legal form: Limited liabilities co.
Web: http://www.qilulinyi-antibiotics.cn/
E-mail: hanwei.chen@qilu-antibiotics.com
Tel: 0534-5059009
Fax: 0534-5059008
Overall payment appraisal:
( ) Excellent (
) Good (X) Average (
) Fair ( ) Poor
( ) Not yet determined
The appraisal serves as a reference to reveal SC's payments habits and
ability to pay. It is based on the 3
weighed factors: Trade payment
experience (through current enquiry with SC's suppliers), our delinquent
payment and our debt collection record concerning SC.
Trade payment experience: SC did not provide any name of
trade/service suppliers and we have no other sources to conduct the enquiry at
present.
Delinquent
payment record: None in our database.
Debt collection record: No overdue amount owed by SC was placed to us for
collection within the last 6 years.
Agricultural Bank of China Ji’nan North Gongye Road Sub-Branch
AC#：32515116601040001394
Relationship:
Normal.
SC’s management declined to release any financial information.
SC is well-known in its industry with a development history of 20 years.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.66.16 |
|
|
1 |
Rs.101.22 |
|
Euro |
1 |
Rs.74.61 |
INFORMATION DETAILS
|
Analysis Done by
: |
KAR |
|
|
|
|
Report Prepared
by : |
TPT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major sections
of this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.